195 related articles for article (PubMed ID: 37302522)
21. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.
Li C; Brand TM; Iida M; Huang S; Armstrong EA; van der Kogel A; Wheeler DL
Discov Med; 2013 Sep; 16(87):79-92. PubMed ID: 23998444
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.
Lim SM; Kim CG; Cho BC
Cancer Res; 2022 Jan; 82(1):18-20. PubMed ID: 34983785
[TBL] [Abstract][Full Text] [Related]
23. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
[TBL] [Abstract][Full Text] [Related]
24. The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.
Trinder A; Ding K; Zhang J
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38231075
[TBL] [Abstract][Full Text] [Related]
25. HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract][Full Text] [Related]
26. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Huang S; Li C; Armstrong EA; Peet CR; Saker J; Amler LC; Sliwkowski MX; Harari PM
Cancer Res; 2013 Jan; 73(2):824-33. PubMed ID: 23172311
[TBL] [Abstract][Full Text] [Related]
27. Selection of Payloads for Antibody-Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study.
Yao B; Gao X; Dan M; Yuan C; Hu X; Sun Z; Hui X; Liu B; Ouyang P; Chen G
AAPS J; 2022 May; 24(4):70. PubMed ID: 35624189
[TBL] [Abstract][Full Text] [Related]
28. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
[TBL] [Abstract][Full Text] [Related]
30. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
31. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
Oliveira M; Falato C; Cejalvo JM; Vila MM; Tolosa P; Salvador-Bofill FJ; Cruz J; Arumi M; Luna AM; Guerra JA; Vidal M; Martínez-Sáez O; Paré L; González-Farré B; Sanfeliu E; Ciruelos E; Espinosa-Bravo M; Pernas S; Izarzugaza Y; Esker S; Fan PD; Parul P; Santhanagopal A; Sellami D; Villacampa G; Ferrero-Cafiero JM; Pascual T; Prat A
Ann Oncol; 2023 Aug; 34(8):670-680. PubMed ID: 37211044
[TBL] [Abstract][Full Text] [Related]
32. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
Wakui H; Yamamoto N; Nakamichi S; Tamura Y; Nokihara H; Yamada Y; Tamura T
Cancer Chemother Pharmacol; 2014 Mar; 73(3):511-6. PubMed ID: 24442032
[TBL] [Abstract][Full Text] [Related]
34. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
35. A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
DaSilva JO; Yang K; Surriga O; Nittoli T; Kunz A; Franklin MC; Delfino FJ; Mao S; Zhao F; Giurleo JT; Kelly MP; Makonnen S; Hickey C; Krueger P; Foster R; Chen Z; Retter MW; Slim R; Young TM; Olson WC; Thurston G; Daly C
Mol Cancer Ther; 2021 Oct; 20(10):1966-1976. PubMed ID: 34315762
[TBL] [Abstract][Full Text] [Related]
36. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
37. Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
He K; Xu J; Liang J; Jiang J; Tang M; Ye X; Zhang Z; Zhang L; Fu B; Li Y; Bai C; Zhang L; Tao W
Mol Cancer Ther; 2019 Jun; 18(6):1104-1114. PubMed ID: 30962319
[TBL] [Abstract][Full Text] [Related]
38. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
39. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
Pascual T; Oliveira M; Ciruelos E; Bellet Ezquerra M; Saura C; Gavilá J; Pernas S; Muñoz M; Vidal MJ; Margelí Vila M; Cejalvo JM; González-Farré B; Espinosa-Bravo M; Cruz J; Salvador-Bofill FJ; Guerra JA; Luna Barrera AM; Arumi de Dios M; Esker S; Fan PD; Martínez-Sáez O; Villacampa G; Paré L; Ferrero-Cafiero JM; Villagrasa P; Prat A
Front Oncol; 2021; 11():638482. PubMed ID: 33968735
[No Abstract] [Full Text] [Related]
40. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
Chang YF; Lim KH; Chiang YW; Sie ZL; Chang J; Ho AS; Cheng CC
BMC Cancer; 2019 Oct; 19(1):959. PubMed ID: 31619200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]